March 18, 2020 / 10:17 AM / 12 days ago

BRIEF-Ideaya Biosciences Announces Ide196 Monotherapy Phase 2 Dose Selection And Clinical Program Update

March 18 (Reuters) - IDEAYA Biosciences Inc:

* IDEAYA BIOSCIENCES ANNOUNCES IDE196 MONOTHERAPY PHASE 2 DOSE SELECTION AND CLINICAL PROGRAM UPDATE

* IDEAYA BIOSCIENCES INC - TARGETING INITIATION OF IDE196 AND BINIMETINIB COMBINATION CLINICAL TRIAL IN MID-2020

* IDEAYA BIOSCIENCES INC - CASH CURRENTLY ANTICIPATED TO BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO END OF 2021 TO EARLY 2022 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below